Danielle Gerhard, PhD | Mar 22, 2024 | 10+ min read
With the help of directed evolution, scientists inch closer to developing viral vectors that can cross the human blood-brain barrier to deliver gene therapy.
Abcam’s new premium-grade bioactive proteins are highly-active growth factors and cytokines manufactured and designed to meet the specific needs of cell culture, including cell and gene therapy and regenerative medicine.
Damaged lysosomes are repaired by a lipid-based signaling pathway dubbed PITT that could be targeted to treat neurodegenerative disease, its discoverers say.
John Hines and Craig M. Crews | May 1, 2017 | 10+ min read
The proteasome’s ability to target and degrade specific proteins is proving useful to researchers studying protein function or developing treatments for diseases.